Contact Us
Drug Search Results
More Filters [+]

SAL-003

Alternative Names: sal-003, sal 003, sal003
Latest Update: 2024-01-17
Latest Update Note: PubMed Publication

Product Description

Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University is developing SAL-003 as a treatment for intervertebral disc degeneration. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/36744257/)

Mechanisms of Action: eiF2A Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SAL-003

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Hypercholesterolemia|Hyperlipidemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20230897

P2

Not yet recruiting

Hyperlipidemia|Hypercholesterolemia

None

CTR20212013

P1

Not yet recruiting

Hyperlipidemia|Hypercholesterolemia

None

Recent News Events

Date

Type

Title

01/17/2024

PubMed

 Model-Informed Dose Selection for a Novel Human Immunoglobulin G4 Derived Monoclonal Antibody Targeting Proprotein Convertase Kwashiorkor Type 9: Insights from Population Pharmacokinetics-Pharmacodynamics and Systems Pharmacology.

01/20/2023

PubMed

 Sal003 alleviated intervertebral disc degeneration by inhibiting apoptosis and extracellular matrix degradation through suppressing endoplasmic reticulum stress pathway in rats.

07/08/2022

PubMed

 Integrated Stress Response Regulation of Corneal Epithelial Cell Motility and Cytokine Production.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions